Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting
Jun Luo(Johns Hopkins University), Ganesh V. Raj(The University of Texas Southwestern Medical Center), Christopher J. Logothetis(The University of Texas MD Anderson Cancer Center), Joshua M. Lang(University of Wisconsin–Madison), Luke A. Selth(Flinders University), Wayne D. Tilley(The University of Adelaide), Charlotte L. Bevan(The London College), Hannelore V. Heemers(Cleveland Clinic), Charles L. Sawyers(Memorial Sloan Kettering Cancer Center), Richard J. Lee(La Roche College), Allen C. Gao(UC Davis Comprehensive Cancer Center), Laura Cato(Harvard University), Ralf Kittler(Southwestern Medical Center), Howard R. Soule(Prostate Cancer Foundation), Nancy L. Weigel(Baylor College of Medicine), Martin Gleave(University of British Columbia), Mayuko Kanayama(Johns Hopkins University), Scott M. Dehm(University of Minnesota), Artem Cherkasov(University of British Columbia), Stephen R. Plymate(VA Puget Sound Health Care System), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Amina Zoubeidi(Cervantes Institute), Robert J. Matusik(Vanderbilt University Medical Center), Steven P. Balk(Beth Israel Deaconess Medical Center), Gerhardt Attard(London Cancer), Kerry L. Burnstein(University of Miami), Yan Dong(Tulane University)
Cited by 130
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k
How To Build and Interpret a Nomogram for Cancer Prognosis
|Journal of Clinical Oncology|2008|3.4k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k